Skip to main content
. 2019 Apr 11;8(4):491. doi: 10.3390/jcm8040491

Table 3.

The clinical course of patients with BKVN.

Patient No. Sex/Age at BKVN (yr) Primary
Disease
Transplant
Year/Donor Type
Onset of
Viremia
after KT
Initial Level 1
(Copies/mL)
Peak Level 2
(Copies/mL)
Biopsy
Grade
Treatment Follow up
after BKVN
Time to Viremia Clearance
1 F/8.0 ATN 2009/D 1.5 mo 16,924 10,165,852 B1 Reduction of IS, IVIG, leflunomide 8.3 yr 89.9 mo
2 F/20.6 Alport 2010/D 60.3 mo 289,699 289,699 B3 Reduction of IS, IVIG, leflunomide 3.0 yr No
3 M/13.1 Alport 2010/L 24.0 mo 41,914 41,914 B1 Reduction of IS, IVIG, leflunomide 6.4 yr No
4 M/15.0 Alport 2014/L 15.9 mo 68,919 2,266,980 B1 Reduction of IS, IVIG, leflunomide, ciprofloxacin, cidofovir 2.2 yr No
5 F/16.8 FSGS 2014/L 4.6 mo 51,102 322,854 ND Reduction of IS, leflunomide, ciprofloxacin 3.8 yr 16.6 mo
6 M/19.5 FSGS 2015/D 6.0 mo 25,555 62,481 ND Reduction of IS, leflunomide 2.4 yr 20.5 mo

1 The value of BK virus load when BK viremia was first detected. 2 The highest value of BK virus load. Abbreviations: BKVN: BK virus nephropathy; S-Cr: serum creatinine; ATN: acute tubular necrosis; VUR: vesicoureteral regurgitation; FSGS: focal segmental glomerulosclerosis; D: deceased; L: living; ND: not done; IS: immunosuppressant; IVIG: intravenous immunoglobulin; mo: months; yr: year.